Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth Pharmaceuticals extends vaccine agreement

Wyeth Pharmaceuticals extends vaccine agreement

16th January 2006

Wyeth is to extend its licensing agreement with the US vaccine firm AlphaVax.

Under an agreement originally signed in 1998 Wyeth gained access to certain core alphavirus vector technologies controlled by AlphaVax to develop vaccines.

The extension of this agreement sees the two companies forming a closer collaboration and includes significantly increased financial terms and an equity investment in AlphaVax by Wyeth.

AlphaVax president and chief executive Peter Young said: “It is clear that vaccines are an increasingly important public health priority in a wide variety of diseases and biological threats, and this reality is driving significant new growth and investment.

“Our Wyeth relationship has played an important part in our development since the inception of our company, and this new agreement is a very gratifying confirmation of not only our technology’s considerable promise but the progress AlphaVax has made as well.”

The financial terms of the agreement have not been disclosed.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.